Home » Stocks » PTCT

PTC Therapeutics, Inc. (PTCT)

Stock Price: $63.53 USD 0.38 (0.60%)
Updated November 25, 4:00 PM EST - Market closed
After-hours: $63.13 -0.40 (-0.63%) Nov 25, 5:00 PM

Stock Price Chart

Key Info

Market Cap 4.34B
Revenue (ttm) 358.36M
Net Income (ttm) -441.48M
Shares Out 68.24M
EPS (ttm) -6.86
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 25
Last Price $63.53
Previous Close $63.15
Change ($) 0.38
Change (%) 0.60%
Day's Open 63.49
Day's Range 62.58 - 64.62
Day's Volume 319,000
52-Week Range 30.79 - 64.62

More Stats

Market Cap 4.34B
Enterprise Value 3.61B
Earnings Date (est) Mar 4, 2021
Ex-Dividend Date n/a
Shares Outstanding 68.24M
Float 65.82M
EPS (basic) -6.88
EPS (diluted) -6.86
FCF / Share -2.78
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 4.51M
Short Ratio 11.13
Short % of Float 6.86%
Beta 1.18
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 12.10
PB Ratio 8.43
Revenue 358.36M
Operating Income -378.80M
Net Income -441.48M
Free Cash Flow -187.74M
Net Cash 726.66M
Net Cash / Share 10.65
Gross Margin 10.43%
Operating Margin -105.70%
Profit Margin -123.20%
FCF Margin -52.39%
ROA -10.26%
ROE -75.17%
ROIC -47.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (13)

Buy 5
Overweight 2
Hold 6
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

$61.58*
(-3.07% downside)
Low
45.0
Current: $63.53
High
90.0
Target: 61.58
*Average 12-month price target from 12 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014201320122011
Revenue30726519482.7136.7725.2534.7033.95105
Revenue Growth15.96%36.19%135.04%124.95%45.64%-27.24%2.21%-67.8%-
Gross Profit29525219082.7136.7725.2534.7033.95105
Operating Income-193-96.35-64.29-132-167-99.41-45.40-26.8130.58
Net Income-252-128-79.00-142-170-93.75-48.1813430.91
Shares Outstanding58.8646.5839.1834.0433.6331.5712.83--
Earnings Per Share-4.27-2.75-2.02-4.17-5.07-2.97-5.1842.504.55
EPS Growth-------834.07%-
Operating Cash Flow-98.64-27.64-10.06-104-124-57.27-46.92-47.93-20.77
Capital Expenditures-45.44-15.53-80.26-1.78-2.72-4.66-0.85-0.19-0.17
Free Cash Flow-144-43.17-90.33-105-127-61.94-47.77-48.12-20.93
Cash & Equivalents6872281912323393151422.73-
Total Debt31415314598.2291.85-0.054.88-
Net Cash / Debt37374.5746.28133247315142-2.16-
Assets1,6241,11939226936533315213.07-
Liabilities1,02976823515013934.7515.3631.89-
Book Value594351156120226298137-99.64-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name PTC Therapeutics, Inc.
Country United States
Employees 754
CEO Stuart W. Peltz

Stock Information

Ticker Symbol PTCT
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: PTCT
IPO Date June 20, 2013

Description

PTC Therapeutics, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) and Emflaza (deflazacort) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients. It is developing Translarna, which is in Phase 2 clinical study for the treatment of nonsense mutation aniridia and nonsense mutation Dravet syndrome/CDKL5; and RG7916 and RO7034067 for the treatment of patients with spinal muscular atrophy, as well as PTC596 and PTC299, a small molecule dihydrooratate dehydrogenase (DHODH) inhibitor that inhibits de novo pyrimidine nucleotide synthesis, which is in Phase 1 clinical development stage to treat cancer patients. The company is also developing gene therapy product candidate that include PTC-AADC for the treatment of Aromatic L-amino acid decarboxylase deficiency. It has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., and the Spinal Muscular Atrophy Foundation to develop and commercialize compounds identified under its spinal muscular atrophy sponsored research program; research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey.